The FDA granted Pfizer orphan status for maplirpacept, its potential treatment of acute myeloid leukemia.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PFE:
- Weight-loss drug developers rise after Roche agrees to buy Carmot
- Notable open interest changes for December 4th
- BofA expects ‘modest weakness’ in Pfizer on danuglipron tolerability concerns
- Pfizer weight loss data update disappointing, says JPMorgan
- Pfizer (NYSE:PFE) Slides as Weight Loss Drug Suffers Setback